RPMI8226细胞

RPMI-8226/RPMI-8226细胞系/RPMI-8226细胞株/RPMI-8226人多发性骨髓瘤细胞

Cell line name RPMI-8226

Synonyms RPMI 8226; RPMI.8226; RPMI8226; RPMI no. 8226; RPMI no 8226; RPMI #8226; 8226; RPMI 8226/S; RPMI-8226S; RPMI8226/S; 8226/S; Roswell Park Memorial Institute 8226; GM02132; GM2132; GM 2132; GM02132C; Simpson

Accession CVCL_0014

Secondary accession CVCL_7353

Resource Identification Initiative To cite this cell line use: RPMI-8226 (RRID:CVCL_0014)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: LL-100 blood cancer cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: NCI-60 cancer cell line panel.

Part of: NCI-7 clinical proteomics reference material cell line panel.

Population: African American.

Characteristics: Produces IgG lambda (PubMed=6042436; ATCC=CCL-155).

Doubling time: 60 hours (PubMed=25984343); ~60-70 hours (DSMZ=ACC-402); 33.5 hours (NCI-DTP=RPMI-8226).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: CNV analysis.

Omics: CRISPR phenotypic screen.

Omics: Deep antibody staining analysis.

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Fluorescence phenotype profiling.

Omics: lncRNA expression profiling.

Omics: Metabolome analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck, Catherine.

Misspelling: RPMI-8266; Note=Occasionally.

Misspelling: RPMI-8826; Cosmic=875867.

Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.

Cell type: B-cell; CL=CL_0000236.

Mulivor R.A., Suchy S.F.

1992/1993 catalog of cell lines. NIGMS human genetic mutant cell repository. 16th edition. October 1992.

(In misc. document) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda; USA (1992)

 

PubMed=1373872

Mazars G.-R., Portier M., Zhang X.-G., Jourdan M., Bataille R., Theillet C., Klein B.

Mutations of the p53 gene in human myeloma cell lines.

Oncogene 7:1015-1018(1992)

 

PubMed=8943038; DOI=10.1073/pnas.93.24.13931; PMCID=PMC19472

Bergsagel P.L., Chesi M., Nardini E., Brents L.A., Kirby S.L., Kuehl W.M.

Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.

Proc. Natl. Acad. Sci. U.S.A. 93:13931-13936(1996)

 

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D

Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Screening the p53 status of human cell lines using a yeast functional assay.

Mol. Carcinog. 19:243-253(1997)

 

PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x; PMCID=PMC5921588

Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y., Hirai H.

Frameshift mutations of the hMSH6 gene in human leukemia cell lines.

Jpn. J. Cancer Res. 89:33-39(1998)

 

PubMed=10087940; DOI=10.1016/S0165-4608(98)00157-5

Kuipers J., Vaandrager J.W., Weghuis D.O., Pearson P.L., Scheres J., Lokhorst H.M., Clevers H.C., Bast B.J.E.G.

Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines.

Cancer Genet. Cytogenet. 109:99-107(1999)

 

PubMed=10557056; DOI=10.1038/sj.leu.2401563

Yoshida S., Nakazawa N., Iida S., Hayami Y., Sato S., Wakita A., Shimizu S., Taniwaki M., Ueda R.

Detection of MUM1/IRF4-IgH fusion in multiple myeloma.

Leukemia 13:1812-1816(1999)

 

PubMed=10583232; DOI=10.1046/j.1365-2141.1999.01705.x

Puthier D., Derenne S., Barille S., Moreau P., Harousseau J.-L., Bataille R., Amiot M.

Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.

Br. J. Haematol. 107:392-395(1999)

 

DOI=10.1007/0-306-46877-8_4

Jernberg-Wiklund H., Nilsson K.

Multiple myeloma cell lines.

(In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000)

 

PubMed=10700174; DOI=10.1038/73432

Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.

Systematic variation in gene expression patterns in human cancer cell lines.

Nat. Genet. 24:227-235(2000)

 

PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2

Drexler H.G., Matsuo Y.

Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.

Leuk. Res. 24:681-703(2000)

 

PubMed=11001907; DOI=10.1182/blood.V96.7.2528

Borset M., Hjertner O., Yaccoby S., Epstein J., Sanderson R.D.

Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins.

Blood 96:2528-2536(2000)

 

DOI=10.1016/B978-0-12-221970-2.50457-5

Drexler H.G.

The leukemia-lymphoma cell line factsbook.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001)

 

PubMed=11154231; DOI=10.1182/blood.V97.2.516

Hjertner O., Hjorth-Hansen H., Borset M., Seidel C., Waage A., Sundan A.

Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells.

Blood 97:516-522(2001)

 

PubMed=11157491; DOI=10.1182/blood.V97.3.729

Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A., Kuehl W.M., Bergsagel P.L.

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.

Blood 97:729-736(2001)

 

PubMed=12068308; DOI=10.1038/nature00766

Davies H.R., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Mutations of the BRAF gene in human cancer.

Nature 417:949-954(2002)

 

PubMed=14555701

Shammas M.A., Shmookler Reis R.J., Akiyama M., Koley H., Chauhan D., Hideshima T., Goyal R.K., Hurley L.H., Anderson K.C., Munshi N.C.

Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma.

Mol. Cancer Ther. 2:825-833(2003)